Literature DB >> 6274946

The 24-h urinary cyclic adenosine 3', 5' monophosphate/creatinine ratio: an useful approach to the diagnosis of parathyroid disorders and function.

A Caniggia, R Nuti, M Galli.   

Abstract

24-h urinary cyclic adenosine 3', 5'-monophosphate/creatinine (cAMP/Cr) ratio was assessed in 10 patients with hypoparathyroidism, 6 with primary hyperparathyroidism, 7 with normocalcemic hypercalciuria and recurrent nephrolithiasis, 14 with osteomalacia, 25 with Paget's disease and 53 with symptomatic postmenopausal osteoporosis. In hypoparathyroid subjects the mean values of 24 h cAMP/Cr ratio were significantly lower than the control values, whereas in patients with parathyroid adenoma the mean values were higher and fell after parathyroid surgery. Patients with nephrolithiasis due to absorptive hypercalciuria showed low or normal cAMP/Cr ratio, whereas in those with osteomalacia and mean values of cAMP/Cr ratio were significantly higher than the control values and decreased after vitamin D treatment. The mean value of the 24 h urine cAMP/Cr ratio was normal in patients with Paget's disease or postmenopausal osteoporosis and increased significantly after long term treatment with calcitonin or diphosphonate. This increase paralleled a significant decrease of calcium plasma level. A significant improvement of fractional calcium absorption was observed in women with postmenopausal osteoporosis at the end of treatment with calcitonin or diphosphonate.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6274946     DOI: 10.1007/BF03349445

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  27 in total

1.  Evaluation of calcium urolithiasis in ambulatory patients: comparison of results with those of inpatient evaluation.

Authors:  C Y Pak; C Fetner; J Townsend; L Brinkley; C Northcutt; D E Barilla; M Kadesky; P Peters
Journal:  Am J Med       Date:  1978-06       Impact factor: 4.965

2.  Evaluation of urinary cyclic 3'5'-adenosine monophosphate excretion in the differential diagnosis of hypercalcemia.

Authors:  P H Dohan; K Yamashita; P R Larsen; B Davis; L Deftos; J B Field
Journal:  J Clin Endocrinol Metab       Date:  1972-12       Impact factor: 5.958

3.  Renal tubular localization of parathyroid hormone induced urinary cyclic adenosine 3',5'-monophosphate.

Authors:  M T Scurry; G L Pauk
Journal:  Acta Endocrinol (Copenh)       Date:  1974-10

4.  Parathyroid function and the renal excretion of 3'5'-adenylic acid.

Authors:  L R Chase; G D Aurbach
Journal:  Proc Natl Acad Sci U S A       Date:  1967-08       Impact factor: 11.205

5.  Urinary cyclic adenosine monophosphate in young adults and elderly subjects.

Authors:  C Gennari; M Galli; M Montagnani
Journal:  J Clin Pathol       Date:  1976-01       Impact factor: 3.411

6.  Evidence for secondary hyperparathyroidism in idiopathic hypercalciuria.

Authors:  F L Coe; J M Canterbury; J J Firpo; E Reiss
Journal:  J Clin Invest       Date:  1973-01       Impact factor: 14.808

7.  Renal adenyl cyclase: anatomically separate sites for parathyroid hormone and vasopressin.

Authors:  L R Chase; G D Aurbach
Journal:  Science       Date:  1968-02-02       Impact factor: 47.728

8.  Kinetic parameters and renal clearances of plasma adenosine 3',5'-monophosphate and guanosine 3',5'-monophosphate in man.

Authors:  A E Broadus; N I Kaminsky; J G Hardman; E W Sutherland; G W Liddle
Journal:  J Clin Invest       Date:  1970-12       Impact factor: 14.808

9.  Effects of parathyroid hormone on plasma and urinary adenosine 3',5'-monophosphate in man.

Authors:  N I Kaminsky; A E Broadus; J G Hardman; D J Jones; J H Ball; E W Sutherland; G W Liddle
Journal:  J Clin Invest       Date:  1970-12       Impact factor: 14.808

10.  Renal cyclic adenosine monophosphate: an accurate index of parathyroid function.

Authors:  M K Drezner; F A Neelon; H B Curtis; H E Lebovitz
Journal:  Metabolism       Date:  1976-10       Impact factor: 8.694

View more
  2 in total

1.  25-Hydroxycholecalciferol as an antagonist of adverse corticosteroid effects on phosphate and calcium metabolism in man.

Authors:  R Nuti; A Vattimo; V Turchetti; G Righi
Journal:  J Endocrinol Invest       Date:  1984-10       Impact factor: 4.256

2.  The hormonal form of vitamin D in the pathophysiology and therapy of postmenopausal osteoporosis.

Authors:  A Caniggia; R Nuti; F Loré; A Vattimo
Journal:  J Endocrinol Invest       Date:  1984-08       Impact factor: 4.256

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.